Optimal planning of phase II/III programs for clinical trials with multiple endpoints

DOI10.1002/pst.1861WikidataQ53397556 ScholiaQ53397556MaRDI QIDQ5978237

Meinhard Kieser, Heiko Götte, Marietta Kirchner, Eva Dölger

Publication date: 26 April 2018

Published in: Pharmaceutical Statistics (Search for Journal in Brave)

Related Items

drugdevelopR